Nova Scotia Health | Hepatology Research

Research site

(Unclaimed)

Location

1276 South Park Street, Halifax, Nova Scotia, Canada

Site insights

Top conditions

Top treatments

Rivaroxaban

Levothyroxine

Lemborexant

BAY2927088

Ziltivekimab

NNC0487-0111

Tideglusib

Ticagrelor

Metreleptin

Parent organization

This site is a part of Nova Scotia Health

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 32 total trials

New

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity (HF-POLARIS)

This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or He...

Begins enrollment this month

Obesity

Heart Failure

Drug: Placebo

Drug: NNC0487-0111

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling

Heart Failure

Drug: Placebo

Drug: Ziltivekimab

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (panSOHO)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for...

Enrolling

Advanced Solid Tumors

HER2 Mutation

Drug: BAY2927088

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL (METRE-PL)

This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.

Active, not recruiting

Partial Lipodystrophy

Drug: metreleptin

Drug: Placebo

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy (TaRGET)

The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic ef...

Enrolling

Arrhythmogenic Cardiomyopathy

Arrhythmogenic Right Ventricular Cardiomyopathy

Drug: Placebo

Drug: Tideglusib